Lexicon Pharma (LXRX) Tops Q4 EPS by 14c, Beats on Revenues
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.05 +0.49%
EPS Growth %: -50.0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -50.0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.27), $0.14 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $33 million versus the consensus estimate of $29.98 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Amneal gets FDA approval for lanreotide injection, launches immediately
- Corpay agrees to $100M FTC settlement over marketing practices
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
